In 2022, GreenLight anticipates receiving US regulatory approval of its RNA-based product for controlling the Colorado potato beetle.
Recently, the company also announced a research partnership agreement with Germains Seed Technology that could lead to the first commercial use of RNA as a seed treatment to control crop diseases and offer options to farmers looking for innovative solutions.
Through the partnership, the two companies will explore synergies between Germains’ seed priming and coating technologies and GreenLight’s dsRNA expertise and ability to cost-effectively scale manufacturing to protect vegetable crops.
In October 2021, GreenLight announced that it had achieved, for the first time, effective field control of fungal pathogens using double-stranded RNA.
“Farmers and agribusinesses are looking for effective, affordable, and sustainable alternatives to traditional crop protection, particularly as environmental and market pressures to do so continue to increase,” Mark Singleton, GreenLight’s Senior Vice President of Technology & External Innovation said.
The company has seven agricultural products in development with an addressable market of USD 6bn that it plans to launch by 2026.
